ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2020
Crimean-Congo haemorrhagic fever (CCHF) virus-specific antibody detection in blood donors, Castile-León, Spain, summer 2017 and 2018.
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 30 citations in OpenAlex.
- Crimean-Congo hemorrhagic fever: An emerging threat in Europe.Virologica Sinica · 2026Review
- Seroprevalence of tick-borne infections in blood donors in Europe: a systematic review.New microbes and new infections · 2025Review
- Serological evaluation of Crimean-Congo Hemorrhagic fever in humans with High-Risk professional exposure and in residual sera collected in 2022-2023 across Corsica (France).One health (Amsterdam, Netherlands) · 2025Article
- Control strategies for emerging infectious diseases: Crimean-Congo hemorrhagic fever management.Health science reports · 2024Article
- Third International Conference on Crimean-Congo Hemorrhagic Fever in Thessaloniki, Greece, September 19-21, 2023.Antiviral research · 2024Review
- Seroprevalence of Crimean-Congo hemorrhagic fever virus in the population of Turkestan region.Le infezioni in medicina · 2024Article
- Seroprevalence of Crimean Congo Hemorrhagic Fever Virus in Occupational Settings: Systematic Review and Meta-Analysis.Tropical medicine and infectious disease · 2023Review
- Crimean-Congo Hemorrhagic Fever, Spain, 2013-2021.Emerging infectious diseases · 2023Review
- Applications of MALDI-TOF Mass Spectrometry to the Identification of Parasites and Arthropod Vectors of Human Diseases.Microorganisms · 2022Review
- First serological evidence of Crimean-Congo haemorrhagic fever virus in transhumant bovines in Italy.Transboundary and emerging diseases · 2022Article
- The spatial pattern of human exposure to Crimean-Congo haemorrhagic fever virus is not consistent with red deer-based risk predictions.Transboundary and emerging diseases · 2022Article
- The impact of climate change and emerging infectious diseases on the blood supply.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Article
- Hotspot of Crimean-Congo Hemorrhagic Fever Virus Seropositivity in Wildlife, Northeastern Spain.Emerging infectious diseases · 2021Article
- First Serological Evidence of Crimean-Congo Hemorrhagic Fever Virus and Rift Valley Fever Virus in Ruminants in Tunisia.Pathogens (Basel, Switzerland) · 2021Article
- Imported Hyalomma ticks in the Netherlands 2018-2020.Parasites & vectors · 2021Article
- Epidemiological Aspects of Crimean-Congo Hemorrhagic Fever in Western Europe: What about the Future?Microorganisms · 2021Review
- New circulation of genotype V of Crimean-Congo haemorrhagic fever virus in humans from Spain.PLoS neglected tropical diseases · 2021Article
- Purification of Crimean-Congo hemorrhagic fever virus nucleoprotein and its utility for serological diagnosis.Scientific reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundCrimean-Congo haemorrhagic fever virus (CCHFV) is considered an emerging or even a probable re-emerging pathogen in southern Europe. Presence of this virus had been reported previously in Spain in 2010.AimWe aimed to evaluate the potential circulation of CCHFV in western Spain with a serosurvey in asymptomatic adults (blood donors).MethodsDuring 2017 and 2018, we conducted a CCHFV serosurvey in randomly selected asymptomatic blood donors from western Spain. Three assays using specific IgG antibodies against CCHFV were performed: the VectoCrimea ELISA test, an in-house ELISA and indirect immunofluorescence (EuroImmun) test with glycoprotein and nucleoprotein.ResultsA total of 516 blood donors participated in this cross-sectional study. The majority of the study participants were male (68.4%), and the mean age was 46.3 years. Most of the participants came from rural areas (86.8%) and 68.6% had contact with animals and 20.9% had animal husbandry practices. One in five participants (109/516, 21.1%) were engaged in at-risk professional activities such as agriculture and shepherding, slaughtering, hunting, veterinary and healthcare work (mainly nursing staff and laboratory technicians). A total of 15.3% of the participants were bitten by ticks in the days or months before the date of sampling. We detected anti-CCHFV IgG antibodies with two diagnostic assays in three of the 516 individuals and with one diagnostic assay in six of the 516 individuals.ConclusionSeroprevalence of CCHFV was between 0.58% and 1.16% in Castile-León, Spain. This is the first study in western Spain that showed circulation of CCHFV in healthy people.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.